Puma Biotechnology, Inc.
NasdaqGS:PBYI Rapport sur les actions
Capitalisation boursière : US$157.6m
Puma Biotechnology Résultats passés
Passé contrôle des critères 5/6 Puma Biotechnology a connu une croissance annuelle moyenne de ses bénéfices de 62.7%, tandis que le secteur Biotechs a vu ses bénéfices augmenter de en hausse à 19.3% par an. Les revenus ont augmenté de en baisse à un taux moyen de 2.7% par an. Le rendement des capitaux propres de Puma Biotechnology est 32.7% et ses marges nettes sont de 9.5%.
Informations clés
62.7%
Taux de croissance des bénéfices
63.1%
Taux de croissance du BPA
Biotechs Croissance de l'industrie 17.0% Taux de croissance des recettes -2.7% Rendement des fonds propres 32.7% Marge nette 9.5% Dernière mise à jour des bénéfices 30 Sep 2024
Mises à jour récentes des performances passées
Afficher toutes les mises à jour
Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest Nov 14
Consensus EPS estimates increase by 16% Nov 14
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 08 Puma Biotechnology, Inc. Revises Earnings Guidance for the Full Year 2024
Puma Biotechnology, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 25
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment? Sep 07
Independent Director recently sold US$81k worth of stock Aug 15
Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop Aug 15
Investor sentiment deteriorates as stock falls 27% Aug 14
Independent Director notifies of intention to sell stock Aug 14
New minor risk - Share price stability Aug 06
New major risk - Revenue and earnings growth Aug 04
Puma Biotechnology, Inc. Provides Earning Guidance for the Third Quarter and Full Year of 2024 Aug 03
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 02
Insufficient new directors Aug 01
Founder recently sold US$81k worth of stock Jul 21
Founder notifies of intention to sell stock Jul 19
Puma Biotechnology, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 19
Investor sentiment improves as stock rises 22% Jul 12
Founder notifies of intention to sell stock Jul 04
The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25% Jun 07
Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today Jun 05
Puma Biotechnology, Inc. Announces Presentation of Findings from A Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (Tbcrc 041) Jun 05
Investor sentiment deteriorates as stock falls 20% May 20
We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings May 09
Puma Biotechnology: A Story In Flux Heading Into Mid-2024 May 05
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind May 03
Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2024 May 03
Puma Biotechnology, Inc., Annual General Meeting, Jun 18, 2024 Apr 28
Puma Biotechnology, Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 20
Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation? Apr 10
Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer Mar 23
Investor sentiment deteriorates as stock falls 15% Mar 18
Consensus EPS estimates increase by 45%, revenue downgraded Mar 07
New minor risk - Shareholder dilution Mar 04
Full year 2023 earnings: EPS misses analyst expectations Mar 03
There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump Mar 01
Puma Biotechnology, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024 Mar 01
Puma Biotechnology, Inc. to Report Q4, 2023 Results on Feb 29, 2024 Feb 16
Puma Biotechnology, Inc. Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer Feb 13
Investor sentiment improves as stock rises 22% Feb 10
New minor risk - Share price stability Jan 18
Founder notifies of intention to sell stock Jan 06
Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden Dec 27
Puma Biotechnology, Inc. Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer Dec 11
Investor sentiment improves as stock rises 15% Nov 27
Independent Director recently sold US$71k worth of stock Nov 12
Independent Director notifies of intention to sell stock Nov 10
Investor sentiment improves as stock rises 19% Nov 09
New major risk - Financial position Nov 03
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 03
Puma Biotechnology, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023 Nov 03
Puma Biotechnology, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 20
Puma Biotechnology, Inc. Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting Oct 15
Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet Sep 08
Puma Biotechnology, Inc. Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer Aug 09
New major risk - Revenue and earnings growth Aug 07
Puma Biotechnology, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023 Aug 06
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 04
Puma Biotechnology, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 23
Founder notifies of intention to sell stock Jul 06
Puma Biotechnology, Inc. Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel Versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting Jun 05
Investor sentiment improves as stock rises 16% May 26
Consensus EPS estimates increase by 32%, revenue downgraded May 11
Investor sentiment improves as stock rises 17% May 11
Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2023 May 06
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 06
Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34% Apr 17
Consensus EPS estimates increase by 240% Mar 09
Full year 2022 earnings released: EPS: US$0 (vs US$0.72 loss in FY 2021) Mar 03
Puma Biotechnology, Inc. to Report Q4, 2022 Results on Mar 02, 2023 Feb 17
Puma Biotechnology, Inc.’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation Feb 02
Founder recently sold US$114k worth of stock Jan 09
Founder notifies of intention to sell stock Jan 08
Investor sentiment deteriorated over the past week Dec 29
Puma Biotechnology, Inc. announced that it has received $2.499996 million in funding Dec 14
We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt Dec 14
Investor sentiment improved over the past week Dec 14
Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium Dec 08
Investor sentiment improved over the past week Nov 21
Price target decreased to US$5.40 Nov 16
Puma Biotechnology, Inc. Announces Update on Defamation Lawsuit Nov 11
Investor sentiment improved over the past week Nov 10
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 05
Forecast to breakeven in 2024 Nov 04
Puma Biotechnology, Inc. Revises Earnings Guidance for the Full Year 2022 Nov 04
Consensus forecasts updated Nov 03
Forecast breakeven date moved forward to 2023 Oct 01
Consensus forecasts updated Sep 22
Puma Biotechnology, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022 Sep 22
Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib Sep 20
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022 Sep 12
Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt Sep 05
Consensus forecasts updated Aug 13
Independent Director recently sold US$89k worth of stock Aug 12
Price target decreased to US$5.40 Aug 09
Price target decreased to US$5.40 Aug 05
Second quarter 2022 earnings released: EPS: US$0.21 (vs US$0.13 loss in 2Q 2021) Aug 05
Puma Biotechnology Non-GAAP EPS of $0.28, revenue of $59.5M Aug 04
Ventilation des recettes et des dépenses
Comment Puma Biotechnology gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes NasdaqGS:PBYI Recettes, dépenses et bénéfices (USD Millions ) Date Recettes Les revenus Dépenses G+A Dépenses de R&D 30 Sep 24 244 23 83 53 30 Jun 24 219 9 89 52 31 Mar 24 227 15 89 51 31 Dec 23 236 22 89 50 30 Sep 23 229 4 97 51 30 Jun 23 230 -2 98 51 31 Mar 23 235 5 94 50 31 Dec 22 228 0 92 52 30 Sep 22 218 10 87 53 30 Jun 22 207 -34 90 60 31 Mar 22 201 -49 108 67 31 Dec 21 253 -29 116 72 30 Sep 21 250 -48 122 82 30 Jun 21 255 -35 126 86 31 Mar 21 272 -27 116 92 31 Dec 20 225 -60 118 98 30 Sep 20 235 -56 120 104 30 Jun 20 241 -42 122 110 31 Mar 20 224 -82 126 123 31 Dec 19 272 -76 140 133 30 Sep 19 280 -95 151 141 30 Jun 19 287 -92 148 147 31 Mar 19 284 -99 155 154 31 Dec 18 251 -114 146 165 30 Sep 18 202 -147 136 177 30 Jun 18 145 -210 140 190 31 Mar 18 94 -243 125 200 31 Dec 17 28 -292 107 208 30 Sep 17 6 -301 92 214 30 Jun 17 0 -289 74 216 31 Mar 17 0 -278 61 217 31 Dec 16 0 -276 54 223 30 Sep 16 0 -265 47 219 30 Jun 16 0 -260 42 219 31 Mar 16 0 -258 35 224 31 Dec 15 0 -239 32 208 30 Sep 15 0 -225 30 196 30 Jun 15 0 -200 25 176 31 Mar 15 0 -175 24 151 31 Dec 14 0 -142 19 123 30 Sep 14 0 -110 14 96 30 Jun 14 0 -89 13 76 31 Mar 14 0 -63 11 52
Des revenus de qualité: PBYI a des bénéfices de haute qualité .
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de PBYI sont plus élevées que l'année dernière PBYI. (9.5%) sont plus élevées que l'année dernière (1.6%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: PBYI est devenue rentable au cours des 5 dernières années, augmentant ses bénéfices de 62.7% par an.
Accélération de la croissance: La croissance des bénéfices de PBYI au cours de l'année écoulée ( 525.3% ) dépasse sa moyenne sur 5 ans ( 62.7% par an).
Bénéfices par rapport au secteur d'activité: La croissance des bénéfices PBYI au cours de l'année écoulée ( 525.3% ) a dépassé celle du secteur Biotechs 16.6%.
Rendement des fonds propres
ROE élevé: Bien que le retour sur capitaux propres ( 32.69% ) de PBYI soit élevé , cette mesure est faussée en raison de son niveau d'endettement élevé.
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
